QURE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against uniQure N.V.

Core Viewpoint - A class action has been filed against uniQure N.V. for allegedly misleading investors regarding the FDA approval likelihood of its leading drug candidate, AMT-130 [1] Allegations - The complaint alleges that uniQure did not fully disclose that the design of its Pivotal Study was not fully approved by the FDA [1] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies [1] Impact of FDA Feedback - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from the Phase I/II studies of AMT-130 would be adequate for BLA submission [1] - Following this announcement, uniQure's stock price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1] Class Action Participation - Shareholders wishing to serve as lead plaintiffs must submit their papers by April 13, 2026 [1] - Participation in the case is not required to be eligible for recovery, and representation is on a contingency fee basis [1]